$180,000.00 in Sales Expected for Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) This Quarter
Brokerages forecast that Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) will report $180,000.00 in sales for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Eiger BioPharmaceuticals’ earnings. The lowest sales estimate is $100,000.00 and the highest is $260,000.00. The business is expected to issue its next earnings results on Friday, March 12th.
According to Zacks, analysts expect that Eiger BioPharmaceuticals will report full year sales of $180,000.00 for the current fiscal year, with estimates ranging from $100,000.00 to $260,000.00. For the next financial year, analysts anticipate that the company will report sales of $53.62 million, with estimates ranging from $3.99 million to $147.10 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Eiger BioPharmaceuticals.
Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings data on Thursday, November 5th. The biotechnology company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.09.
Several institutional investors and hedge funds have recently made changes to their positions in EIGR. BlackRock Inc. grew its stake in shares of Eiger BioPharmaceuticals by 14.2% during the third quarter. BlackRock Inc. now owns 2,246,190 shares of the biotechnology company’s stock worth $18,283,000 after purchasing an additional 278,614 shares in the last quarter. Mangrove Partners grew its position in shares of Eiger BioPharmaceuticals by 15.2% during the third quarter. Mangrove Partners now owns 1,092,394 shares of the biotechnology company’s stock worth $8,892,000 after acquiring an additional 144,542 shares during the last quarter. Assenagon Asset Management S.A. grew its position in shares of Eiger BioPharmaceuticals by 744.3% during the third quarter. Assenagon Asset Management S.A. now owns 555,181 shares of the biotechnology company’s stock worth $4,519,000 after acquiring an additional 489,426 shares during the last quarter. State Street Corp increased its holdings in shares of Eiger BioPharmaceuticals by 0.6% in the 3rd quarter. State Street Corp now owns 462,433 shares of the biotechnology company’s stock valued at $3,764,000 after acquiring an additional 2,568 shares during the period. Finally, P.A.W. Capital Corp raised its position in Eiger BioPharmaceuticals by 20.0% in the 3rd quarter. P.A.W. Capital Corp now owns 360,000 shares of the biotechnology company’s stock valued at $2,930,000 after purchasing an additional 60,000 shares during the last quarter. Institutional investors and hedge funds own 60.55% of the company’s stock.
EIGR stock traded up $0.03 during trading on Wednesday, hitting $11.36. The company had a trading volume of 367,312 shares, compared to its average volume of 532,416. The firm has a market capitalization of $369.56 million, a P/E ratio of -4.67 and a beta of 1.51. The company has a 50 day simple moving average of $10.31 and a 200-day simple moving average of $10.09. Eiger BioPharmaceuticals has a 52-week low of $4.55 and a 52-week high of $15.12. The company has a quick ratio of 6.23, a current ratio of 6.23 and a debt-to-equity ratio of 0.27.
About Eiger BioPharmaceuticals
Eiger BioPharmaceuticals, Inc, a late-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase 3 clinical trial to treat hepatitis delta virus (HDV) infection.
Featured Story: How do analysts define an oversold condition?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Eiger BioPharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.